Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.9 USD | +2.13% | +23.36% | +49.58% |
03:20pm | HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating | MT |
May. 16 | Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024 |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Equities
- IKT Stock
- Revisions Inhibikase Therapeutics, Inc.